Imipramine Starting Dose and Titration for Nocturnal Enuresis in a 10-Year-Old
For a 10-year-old child with nocturnal enuresis, start imipramine at 25 mg orally one hour before bedtime, increase to 50 mg nightly after one week if inadequate response, and do not exceed 75 mg/day (maximum 2.5 mg/kg/day). 1, 2
Baseline Cardiac Evaluation
Before initiating imipramine, obtain a prolonged ECG recording to exclude long QT syndrome if there is any history of:
- Palpitations or syncope in the child
- Sudden cardiac death in the family
- Unstable arrhythmia in the family 1
The FDA label recommends considering a pretreatment ECG to detect underlying rhythm disorders, though this is stated as "may be obtained" rather than mandatory 2. However, given the potentially fatal cardiotoxicity of imipramine overdose, the guideline's more cautious approach is warranted when any cardiac risk factors are present 1.
Dosing Algorithm
Week 1: 25 mg orally, one hour before bedtime 1, 2
Week 2 onward:
- If inadequate response after one week: increase to 50 mg nightly 1, 2
- Children over 12 years may receive up to 75 mg nightly 2
- Never exceed 75 mg/day or 2.5 mg/kg/day 2
For early-night bedwetters specifically, evidence suggests divided dosing may be more effective: 25 mg in mid-afternoon, repeated at bedtime 2.
Therapeutic Monitoring
Evaluate treatment response after 1 month 1. Approximately 50% of children respond to imipramine, with the same response rate in therapy-resistant cases 1.
If partial response occurs:
- Add desmopressin at standard dose (0.2-0.4 mg tablets or 120-240 mg melt formulation)
- Critical safety requirement: Restrict fluid intake during evening and night when combining medications to prevent water intoxication 1
- Evening fluid intake should be ≤200 ml (6 ounces), then nothing until morning 1
If treatment is successful:
- Taper to the lowest effective dose
- Institute regular drug holidays of at least 2 weeks every 3 months to decrease tolerance risk 1
- Taper gradually rather than abrupt discontinuation to reduce relapse tendency 2
Maximum Allowable Dose
Absolute maximum: 75 mg/day or 2.5 mg/kg/day, whichever is lower 2
Doses greater than 75 mg do not enhance efficacy and increase side effects 2. ECG changes of unknown significance have been reported in pediatric patients at doses twice the 2.5 mg/kg/day threshold 2.
Critical Safety Considerations
Imipramine is third-line therapy only due to safety concerns 1. Use only at tertiary care facilities or when:
- Alarm therapy has failed AND
- Family cannot afford desmopressin 1
Overdose prevention:
- Keep medication securely locked and out of reach of younger siblings
- Fatal cardiotoxicity can occur with overdose 1
- Prescribe smallest quantity consistent with good management 2
Common side effects (often appear before beneficial effects):
- Mood changes
- Nausea
- Insomnia 1
Moderate side effects often gradually disappear even if treatment continues 1.
Monitoring During Treatment
Watch for warning signs requiring immediate attention:
- Suicidality or unusual behavioral changes (especially in first few months or with dose changes) 2
- Symptoms suggesting emerging suicidality: anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia 2
Therapeutic drug monitoring considerations: Research shows optimal effect occurs when steady-state levels of imipramine + desipramine exceed 60-80 ng/mL 3, 4, though routine monitoring is not standard practice. The effective concentration in enuresis is 3-4 times lower than in antidepressive therapy 3.
Treatment Duration and Discontinuation
After adequate therapeutic trial with favorable response, institute a drug-free period 2. Children who relapse when discontinued do not always respond to subsequent treatment courses 2. High relapse rates (up to 50%) are documented 5, making regular drug holidays essential to assess ongoing need 1.